Connor Richardson

• BSc (Hons) Biomedical Sciences
• Determination of homologous recombination status and Poly(ADP Ribose) Polymerase inhibitor sensitivity in lung cancer cell lines

A new class of drugs, PARP inhibitors, are being tested in clinical trials to treat certain cancers. PARP inhibitors work well in treating cancers with defects in a DNA repair pathway, homologous recombination repair (HRR), which is associated with mutations in hereditary breast and ovarian cancer genes; BRCA1/2. Emerging research indicates that more genes are involved in HRR defects, and PARP inhibitors may be useful in the treatment of other cancers. This research will look at human lung cancer cell lines and test whether they have defective HRR and if PARP inhibitors stop these cells growing in a laboratory setting.

Funded by: Newcastle University